Repurposed Effect of 177Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma

Mohamad K. Elajami; Lorena P. Burton; Hisham F. Bahmad; Gerard Chaaya; Michael Schwartz

doi:10.3390/curroncol29100594

Repurposed Effect of ¹⁷⁷Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma

Mohamad K. Elajami, Lorena P. Burton, Hisham F. Bahmad, Gerard Chaaya, Michael Schwartz

Academic Institute

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Mantle cell lymphoma (MCL) is an uncommon subcategory of non-Hodgkin lymphoma (NHL). Pathogenesis primarily includes overexpression of CCND1 and SOX11 along with other molecular aberrations. Lutetium ¹⁷⁷Lu-DOTATATE is a radiolabeled somatostatin analogue used for the treatment of gastrointestinal neuroendocrine tumors. There are no clinical data supporting the use of Lutetium ¹⁷⁷Lu-DOTATATE in the treatment of lymphoma. We describe the case of an 84-year-old man with a history of MCL and carcinoid tumor of the lung. Following progression of the carcinoid malignancy, the patient was treated with Lutetium ¹⁷⁷Lu-DOTATATE. After treatment, there was an overall improvement of the patient’s MCL that was demonstrated by stable lymphadenopathy on serial CT scans and down-trend of the absolute lymphocyte count. Therefore, we hypothesize that ¹⁷⁷Lu-DOTATATE might have a role and can be repurposed for treating MCL.

Original language	English (US)
Pages (from-to)	7552-7557
Number of pages	6
Journal	Current Oncology
Volume	29
Issue number	10
DOIs	https://doi.org/10.3390/curroncol29100594
State	Published - Oct 2022

Keywords

DOTATATE
carcinoid
case report
drug repurposing
mantle cell lymphoma

ASJC Scopus subject areas

Oncology

Access to Document

10.3390/curroncol29100594

Cite this

@article{0958eb66c9ee488c88ae0b43c41a48eb,

title = "Repurposed Effect of 177Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma",

abstract = "Mantle cell lymphoma (MCL) is an uncommon subcategory of non-Hodgkin lymphoma (NHL). Pathogenesis primarily includes overexpression of CCND1 and SOX11 along with other molecular aberrations. Lutetium 177Lu-DOTATATE is a radiolabeled somatostatin analogue used for the treatment of gastrointestinal neuroendocrine tumors. There are no clinical data supporting the use of Lutetium 177Lu-DOTATATE in the treatment of lymphoma. We describe the case of an 84-year-old man with a history of MCL and carcinoid tumor of the lung. Following progression of the carcinoid malignancy, the patient was treated with Lutetium 177Lu-DOTATATE. After treatment, there was an overall improvement of the patient{\textquoteright}s MCL that was demonstrated by stable lymphadenopathy on serial CT scans and down-trend of the absolute lymphocyte count. Therefore, we hypothesize that 177Lu-DOTATATE might have a role and can be repurposed for treating MCL.",

keywords = "DOTATATE, carcinoid, case report, drug repurposing, mantle cell lymphoma",

author = "Elajami, \{Mohamad K.\} and Burton, \{Lorena P.\} and Bahmad, \{Hisham F.\} and Gerard Chaaya and Michael Schwartz",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = oct,

doi = "10.3390/curroncol29100594",

language = "English (US)",

volume = "29",

pages = "7552--7557",

journal = "Current Oncology",

issn = "1198-0052",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "10",

}

TY - JOUR

T1 - Repurposed Effect of 177Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma

AU - Elajami, Mohamad K.

AU - Burton, Lorena P.

AU - Bahmad, Hisham F.

AU - Chaaya, Gerard

AU - Schwartz, Michael

PY - 2022/10

Y1 - 2022/10

N2 - Mantle cell lymphoma (MCL) is an uncommon subcategory of non-Hodgkin lymphoma (NHL). Pathogenesis primarily includes overexpression of CCND1 and SOX11 along with other molecular aberrations. Lutetium 177Lu-DOTATATE is a radiolabeled somatostatin analogue used for the treatment of gastrointestinal neuroendocrine tumors. There are no clinical data supporting the use of Lutetium 177Lu-DOTATATE in the treatment of lymphoma. We describe the case of an 84-year-old man with a history of MCL and carcinoid tumor of the lung. Following progression of the carcinoid malignancy, the patient was treated with Lutetium 177Lu-DOTATATE. After treatment, there was an overall improvement of the patient’s MCL that was demonstrated by stable lymphadenopathy on serial CT scans and down-trend of the absolute lymphocyte count. Therefore, we hypothesize that 177Lu-DOTATATE might have a role and can be repurposed for treating MCL.

AB - Mantle cell lymphoma (MCL) is an uncommon subcategory of non-Hodgkin lymphoma (NHL). Pathogenesis primarily includes overexpression of CCND1 and SOX11 along with other molecular aberrations. Lutetium 177Lu-DOTATATE is a radiolabeled somatostatin analogue used for the treatment of gastrointestinal neuroendocrine tumors. There are no clinical data supporting the use of Lutetium 177Lu-DOTATATE in the treatment of lymphoma. We describe the case of an 84-year-old man with a history of MCL and carcinoid tumor of the lung. Following progression of the carcinoid malignancy, the patient was treated with Lutetium 177Lu-DOTATATE. After treatment, there was an overall improvement of the patient’s MCL that was demonstrated by stable lymphadenopathy on serial CT scans and down-trend of the absolute lymphocyte count. Therefore, we hypothesize that 177Lu-DOTATATE might have a role and can be repurposed for treating MCL.

KW - DOTATATE

KW - carcinoid

KW - case report

KW - drug repurposing

KW - mantle cell lymphoma

UR - https://www.scopus.com/pages/publications/85140492727

UR - https://www.scopus.com/inward/citedby.url?scp=85140492727&partnerID=8YFLogxK

U2 - 10.3390/curroncol29100594

DO - 10.3390/curroncol29100594

M3 - Article

C2 - 36290871

AN - SCOPUS:85140492727

SN - 1198-0052

VL - 29

SP - 7552

EP - 7557

JO - Current Oncology

JF - Current Oncology

IS - 10

ER -